A broad group of 14 organisations, working in the European clinical trial sector, have issued a warning that without urgent implementation of the Life Science Strategy (LSS), Europe’s clinical trial eco-system is in a perilous situation. The stakeholders—including academic and industry sponsors, investigators, and professional societies—formed earlier… Read More
CEOs of the research-based pharmaceutical industry have issued a stark warning to the European Commission that unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US. A survey of European Federation of Pharmaceutical Industries and… Read More
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has supported the use of artificial intelligence (AI) to deliver benefit for patients, life science companies and society, in response to the EU Artificial Intelligence (AI) Act. The AI Act, which bans certain AI applications that it… Read More
Plans to overhaul the EU regulation on rare disease therapies risk undermining two decades of progress, a new report claims. The assessment, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA), was conducted by Dolon, a strategic consultancy specialising in rare diseases. Read More
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a series of reports about the availability of new medicines throughout Europe. EFPIA’s 2022 Patient WAIT Indicator tracks the availability of new medicines and length of time it takes patients to get them in 37… Read More
DDW’s Diana Spencer explores the European Commission’s proposed changes to EU pharmaceutical legislation, the reaction from industry and possible impact on smaller companies. The European Commission (EC) has proposed the largest reform to the EU’s pharmaceutical legislation in over 20 years. The EC says the revisions will make the… Read More
New EU legislation designed to improve public health is delaying clinical trials and blocking access to new treatments for cancer and rare diseases, says the European Federation of Pharmaceutical Industries and Associations (EFPIA). The number of clinical trials delayed is expected to run into the hundreds,… Read More
With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. … Read More
